MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E‐mutant colorectal adenocarcinoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1878-0261|12|2|224-238

ISSN： 1574-7891

Source： Molecular Oncology, Vol.12, Iss.2, 2018-02, pp. : 224-238

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Mutations in the Serine Protease Inhibitor Kazal Type 1 (SPINK1) Gene in Japanese Patients with Pancreatitis

By  

Pancreatology, Vol. 5, Iss. 4-5, 2005-06 ,pp. : 354-360

Karger

Access to resources Recommend Favorite

Serine protease inhibitor Kazal type 1 and epidermal growth factor receptor are expressed in pancreatic tubular adenocarcinoma, intraductal papillary mucinous neoplasm, and pancreatic intraepithelial neoplasia

By  

JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, Vol. 20, Iss. 6, 2013-08 ,pp. : 620-627

John Wiley & Sons Inc

Access to resources Recommend Favorite

BRAF Mutation (V600E) Prevalence in Mexican Patients Diagnosed with Melanoma

By  

Case Reports in Oncology, Vol. 9, Iss. 1, 2016-04 ,pp. : 241-245

Karger

Access to resources Recommend Favorite

BRAF V600E mutational status in bile duct adenomas and hamartomas

By  

HISTOPATHOLOGY, Vol. 67, Iss. 4, 2015-10 ,pp. : 562-567

John Wiley & Sons Inc

Access to resources Recommend Favorite

BRAF V600E and loss of heterozygosity assessment in benign oralneural tumours

By  

JOURNAL OF ORAL PATHOLOGY & MEDICINE, Vol. 44, Iss. 8, 2015-09 ,pp. : 634-637

John Wiley & Sons Inc

Access to resources Recommend Favorite